# A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration

> **NCT05126966** · PHASE3 · WITHDRAWN · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab
- **DRUG:** Aflibercept
- **DEVICE:** Port Delivery System with ranibizumab (PDS)

## Key facts

- **NCT ID:** NCT05126966
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-12-29
- **Primary completion:** 2025-01-31
- **Final completion:** 2026-01-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Roche/Genentech has initiated an immediate pause of all new PDS implantations because the implants from commercial supply in the clinical studies did not meet the filed specifications for the intended use
- **Last updated:** 2024-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05126966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05126966, "A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05126966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*